TARA
insider transactionsProtara Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-29.4K
0 buy · 29.4K sell
Net value · 365d
-$3.1M
$0 in · $3.1M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
14
0 buy · 29.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
766 sh
Own New
-
Grant·A
Director
$0
454 sh
Own +2%
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$37.5K
673 sh · $55.75
Own New
-
Other·F
Chief Commercial Officer
$26.1K
6.0K sh · $4.34
Own -8%
-
Sell·S
Director · 10b5-1
$41.6K
80 sh · $519.98
Own -0%
-
Sell·S
Director · 10b5-1
$405.7K
782 sh · $518.76
Own -3%
-
Sell·S
Director · 10b5-1
$774.8K
1.5K sh · $517.59
Own -6%
-
Sell·S
Director · 10b5-1
$373.7K
723 sh · $516.87
Own -3%
-
Sell·S
Director · 10b5-1
$339.0K
657 sh · $515.92
Own -3%
-
Sell·S
Director · 10b5-1
$176.5K
343 sh · $514.67
Own -1%
-
Sell·S
Director · 10b5-1
$20.5K
40 sh · $512.97
Own -0%
-
Sell·S
Director · 10b5-1
$225.0K
439 sh · $512.50
Own -2%
-
Sell·S
Director · 10b5-1
$312.0K
610 sh · $511.40
Own -2%
-
Sell·S
Director · 10b5-1
$77.1K
151 sh · $510.36
Own -1%
-
Sell·S
Director · 10b5-1
$162.6K
320 sh · $508.24
Own -1%
-
Sell·S
Director · 10b5-1
$20.3K
40 sh · $506.68
Own -0%
-
Sell·S
Chief R&D Officer
$6.1K
1.1K sh · $5.40
Own -1%
-
Sell·S
Chief R&D Officer
$118.9K
22.6K sh · $5.26
Own -19%
-
Exercise·M
Director
$0
2.5K sh
Own New
-
Exercise·M
Director
$18.4K
2.5K sh · $7.36
Own +10%
-
Exercise·M
Director
$0
4.0K sh
Own New
-
Exercise·M
Director
$65.8K
4.0K sh · $16.46
Own +19%
-
Other·F
Jesse Shefferman KEY
CEO and President
$58.2K
8.7K sh · $6.67
Own -1%
-
Other·F
Chf Scientific Operations Off
$24.8K
3.7K sh · $6.67
Own -3%
-
Other·F
VP, Controller
$9.7K
1.5K sh · $6.67
Own -3%
-
Other·F
Patrick Fabbio KEY
Chief Financial Officer
$21.8K
3.3K sh · $6.67
Own -5%
-
Other·F
Jesse Shefferman KEY
CEO and President
$91.4K
16.3K sh · $5.60
Own -2%
-
Other·F
Chf Scientific Operations Off
$36.8K
6.6K sh · $5.60
Own -5%
-
Other·F
VP, Controller
$11.9K
2.1K sh · $5.60
Own -5%
-
Other·F
Patrick Fabbio KEY
Chief Financial Officer
$17.2K
3.1K sh · $5.60
Own -4%
-
Grant·A
Jesse Shefferman KEY
CEO and President
$0
524.0K sh
Own New
-
Grant·A
Jesse Shefferman KEY
CEO and President
$0
87.0K sh
Own +9%
-
Grant·A
Chf Scientific Operations Off
$0
180.0K sh
Own New
-
Grant·A
Chf Scientific Operations Off
$0
30.0K sh
Own +30%
-
Grant·A
Chief Medical Officer
$0
158.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
26.0K sh
Own +50%
-
Grant·A
VP, Controller
$0
55.0K sh
Own New
-
Grant·A
VP, Controller
$0
9.5K sh
Own +26%
-
Grant·A
Patrick Fabbio KEY
Chief Financial Officer
$0
175.0K sh
Own New
-
Grant·A
Patrick Fabbio KEY
Chief Financial Officer
$0
28.0K sh
Own +66%
-
Grant·A
Chief Commercial Officer
$0
158.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
26.0K sh
Own +52%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Richard S Levy | Grant A | 766 | $0 |
| Jun 17, 2026 | Richard S Levy | Grant A | 454 | $0 |
| Jun 15, 2026 | Michael Edward Solomon | Grant A | 31.0K | $0 |
| Jun 15, 2026 | Cynthia Smith | Grant A | 31.0K | $0 |
| Jun 15, 2026 | Gregory Sargen | Grant A | 31.0K | $0 |
| Jun 15, 2026 | Richard S Levy | Grant A | 31.0K | $0 |
| Jun 15, 2026 | Jane Huang | Grant A | 31.0K | $0 |
| Jun 15, 2026 | Roger Garceau | Grant A | 31.0K | $0 |
| Jun 15, 2026 | Barry P Flannelly | Grant A | 31.0K | $0 |
| Jun 15, 2026 | Luke M Beshar | Grant A | 31.0K | $0 |
| Jun 9, 2026 | William Conkling | Grant A | 673 | $37.5K |
| Jun 2, 2026 | William Conkling | Other F | 6.0K | $26.1K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 80 | $41.6K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 782 | $405.7K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 1.5K | $774.8K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 723 | $373.7K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 657 | $339.0K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 343 | $176.5K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 40 | $20.5K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 439 | $225.0K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 610 | $312.0K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 151 | $77.1K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 320 | $162.6K |
| May 22, 2026 | Richard S Levy 10b5-1 | Sell S | 40 | $20.3K |
| Apr 8, 2026 | Jacqueline Zummo | Sell S | 1.1K | $6.1K |
| Apr 1, 2026 | Jacqueline Zummo | Sell S | 22.6K | $118.9K |
| Feb 23, 2026 | Richard S Levy | Exercise M | 2.5K | $0 |
| Feb 23, 2026 | Richard S Levy | Exercise M | 2.5K | $18.4K |
| Jan 26, 2026 | Richard S Levy | Exercise M | 4.0K | $0 |
| Jan 26, 2026 | Richard S Levy | Exercise M | 4.0K | $65.8K |
| Jan 26, 2026 | Jesse Shefferman KEY | Other F | 8.7K | $58.2K |
| Jan 26, 2026 | Jacqueline Zummo | Other F | 3.7K | $24.8K |
| Jan 26, 2026 | Hannah Fry | Other F | 1.5K | $9.7K |
| Jan 26, 2026 | Patrick Fabbio KEY | Other F | 3.3K | $21.8K |
| Jan 20, 2026 | Jesse Shefferman KEY | Other F | 16.3K | $91.4K |
| Jan 20, 2026 | Jacqueline Zummo | Other F | 6.6K | $36.8K |
| Jan 20, 2026 | Hannah Fry | Other F | 2.1K | $11.9K |
| Jan 20, 2026 | Patrick Fabbio KEY | Other F | 3.1K | $17.2K |
| Jan 16, 2026 | Jesse Shefferman KEY | Grant A | 524.0K | $0 |
| Jan 16, 2026 | Jesse Shefferman KEY | Grant A | 87.0K | $0 |
| Jan 16, 2026 | Jacqueline Zummo | Grant A | 180.0K | $0 |
| Jan 16, 2026 | Jacqueline Zummo | Grant A | 30.0K | $0 |
| Jan 16, 2026 | Leonardo Viana Nicacio | Grant A | 158.0K | $0 |
| Jan 16, 2026 | Leonardo Viana Nicacio | Grant A | 26.0K | $0 |
| Jan 16, 2026 | Hannah Fry | Grant A | 55.0K | $0 |
| Jan 16, 2026 | Hannah Fry | Grant A | 9.5K | $0 |
| Jan 16, 2026 | Patrick Fabbio KEY | Grant A | 175.0K | $0 |
| Jan 16, 2026 | Patrick Fabbio KEY | Grant A | 28.0K | $0 |
| Jan 16, 2026 | William Conkling | Grant A | 158.0K | $0 |
| Jan 16, 2026 | William Conkling | Grant A | 26.0K | $0 |
About TARA insider trading
This page tracks insider transactions for Protara Therapeutics, Inc. (TARA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.